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This study compared the immune and stress response of oral con-
traceptive users (WomenOC; n = 9) to normally-menstruating 
women (WomenNM; n = 9) at rest and during exercise in temper-
ate (TEMP; 22°C) and hot (HEAT; 35°C) conditions. Participants 
performed a 3-stage cycling trial in each condition at 90% (Stage 
1; 30 min), 135% (Stage 2; 15 min), and 180% (Stage 3; 7.5 min) 
of lactate threshold 1. C-reactive protein (CRP) and immune cell 
counts were measured at rest, and serum cytokines (IL-1β, IL-
1RA, IL-6, IL-8, IL-10, and TNF-α) and salivary cortisol were 
evaluated before and after exercise in both the TEMP and HEAT 
conditions. There were no differences in resting immune cell 
counts between groups, nor any differences in cortisol or any of 
the pro- or anti-inflammatory cytokines measured at rest or after 
completion of the exercise trials (p > 0.05). However, a trend for 
a higher resting CRP concentration was observed in WomenOC 
relative to WomenNM (1.102 ± 1.182 and 0.326 ± 0.228, respec-
tively, p = 0.07). The results obtained in the current study indicate 
similar immunoendocrine function in WomenOC and Wom-
enNM both at rest and after exercise in temperate and hot envi-
ronments. 
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Regular physical activity enhances immune function 
(Gleeson, 2007; Petersen and Pedersen, 2005). However, 
acute bouts of intense endurance exercise or periods of 
intensified training can have an immunodepressive effect, 
subsequently resulting in an increased likelihood of illness 
and infection (Gleeson, 2007). This may be of particular 
consequence for athletes, as even minor infections may 
result in decrements to exercise performance and a reduced 
capacity for heavy training (Roberts, 1986). Heat exposure 
is another factor that can compromise immune function via 
an increase in pro-inflammatory cytokine concentrations 
(Bouchama and Knochel, 2002; Sawka et al., 2011), and 
there is some evidence to suggest that performing exercise 
in a hot environment can exacerbate the immune response 
(Peake et al., 2008). Exercising in the heat also stimulates 
the production of the stress hormone cortisol (Brenner et 
al., 1997; Niess et al., 2003), which has a known 
immunomodulatory effect (Walsh and Whitham, 2006). If 
prolonged or severe, these endocrine and immune 
disturbances can contribute to the pathology of heat stroke 
(Lim and Mackinnon, 2006).   
Sex hormones also modulate the immune system 
(Schuurs and Verheul, 1990), and it is well established that 
oral contraceptives (OC) change the hormonal milieu 
(Wiegratz et al., 2003). Given the relationship between sex 
hormones and immunity, it is perhaps surprising that 
relatively little research has investigated the role of 
exogenous female sex steroids on the modulation of 
immune function. Giraldo et al. (2008) previously 
demonstrated that OC use improves inflammatory status in 
untrained women (i.e., by lowering neutrophil activation 
and interleukin (IL)-8 concentrations and increasing the 
concentration of IL-13), and stated that this greater anti-
inflammatory environment is likely related to the lower 
concentration of endogenous estrogen when compared to 
normally-menstruating women. Conversely, Timmons et 
al. (2005) observed increases in resting leukocyte counts in 
OC users compared to non-users, which could be indicative 
of inflammation. The same study also observed ~80% 
greater exercise-induced IL-6 concentrations in normally-
menstruating women during the follicular phase when 
compared to women on OC. While IL-6 can have pro-
inflammatory properties, increased IL-6 concentrations 
after exercise induce an anti-inflammatory environment by 
inhibiting pro-inflammatory (i.e., TNF-α) cytokines and 
facilitating anti-inflammatory cytokine (i.e., IL-1ra, IL-10) 
production (Petersen and Pedersen, 2005). Thus, it is 
possible that the blunted IL-6 response among OC users in 
the Timmons et al. (2005) study reflects a disruption to the 
normal immune response to exercise. Oral contraceptive 
use is also associated with increased C-reactive protein 
(CRP; a biomarker of inflammation and tissue damage) 
concentrations in the general population (Cauci et al., 
2008; Sørensen et al., 2014; van Rooijen et al., 2006) and 
in athletes (Cauci et al., 2017), which could predispose 
users to a higher inflammatory response to physical stress 
and elevate cardiovascular risk (Ridker et al., 2000). It is 
clear, then, that OC use has the potential to influence 
various aspects of the immune response, although further 
research is required to confirm the direction, magnitude, 
and implications of these changes. Importantly, no 
previous study has investigated the combined effect of heat 
and exercise on the immune response of women taking OC. 
Previous studies investigating the stress response 
(i.e., cortisol) during exercise in the heat are limited by the 
exclusive use of male subjects (e.g., Brenner et al., 1997; 
Hoffman et al., 1997; Niess et al., 2003), or the use of 
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female subjects on and off OC but without the potentially 
additive effect of heat exposure (e.g., Boisseau et al., 2013; 
Bonen et al., 1991; Kirschbaum et al., 1996). Even in this 
literature the data are equivocal; one study observed 
increases in free cortisol at rest in OC users compared to 
non-users (Boisseau et al., 2013), while two reported no 
differences in pre-exercise cortisol concentrations (Bonen 
et al., 1991; Kirschbaum et al., 1996). Furthermore, while 
these three studies agree that the cortisol response to 
exercise is blunted in women on OC, Kirschbaum et al. 
(1996) nonetheless reported an increase in free cortisol in 
response to exhaustive cycling exercise in OC users 
(although to a lesser degree than non-users), whereas 
Boisseau et al. (2013) and Bonen et al. (1991) observed no 
exercise-induced changes in cortisol concentration in 
women taking OC. This may be important, as cortisol acts 
as a powerful natural immunosuppressant (Petrovsky, 
2001). Thus, considerably more research is required before 
firm conclusions can be drawn in respect to OC and the 
stress response, and in particular, the cortisol response 
elicited during exercise in the heat.  
This exploratory study investigated the 
immunoendocrine response to exercise in the heat in 
women taking combined monophasic OC when compared 
to normally-menstruating women. This an important 
consideration, as exercising in hot conditions is 
commonplace for both recreational and competitive 
athletes (e.g., the 2020 Olympic Games have been 
scheduled for the peak of the Tokyo summer).  
Specifically, CRP and immune cell counts were measured 
at rest, and pro- and anti-inflammatory cytokines (IL-1β, 
IL-1RA, IL-6, IL-8, IL-10, and TNF-α) and cortisol were 
evaluated in OC users and non-users before and after 





Eighteen recreationally-active women (performing 300-
500 min/wk of moderate-intensity exercise) voluntarily 
participated in this study. Nine of the women were nor-
mally-menstruating (i.e., every 25-32 days) for >12 months 
(WomenNM), while the remaining nine women were tak-
ing a low-dose combined monophasic OC for >12 months 
(WomenOC). WomenOC continued their OC use through-
out the experimental period. None of the participants had 
ever knowingly been pregnant, and they had no docu-
mented history of pulmonary, cardiovascular, or metabolic 
disorders. Written informed consent was provided by par-
ticipants prior to data collection, and ethical approval was 




WomenNM were tested in the follicular phase of their cy-
cle (day 2-6) when endogenous estrogen is low 
(Charkoudian and Johnson, 2000), whilst WomenOC were 
tested during the active phase of the OC pill (day 2-21; 
when exogenous estrogen is administered). As women on 
OC have suppressed endogenous hormone concentrations 
(Burrows and Peters, 2007), these phases were selected to 
isolate the effects (if any) of the synthetic hormones pro-
vided by the OC pill (Cherney et al., 2007). The follicular 
phase was identified by self-report (the participants alerted 
researchers at the onset of menses) and was confirmed via 
blood concentrations of the female sex hormones (see Re-
sults). 
Participants completed three exercise tests, the first 
of which was an incremental cycling test to exhaustion to 
determine the workloads for the subsequent two trials 
(based on lactate threshold 1 [LT1]). Two 3-stage cycling 
trials were then performed, one in a temperate environment 
(TEMP; 22°C) and the other under hot ambient conditions 
(HEAT; 35°C). Room temperature and relative humidity 
were measured continuously throughout all trials (Vantage 
Vue, Davis Instruments, Hayward, USA). The incremental 
cycling test was performed 4 wk before the 3-stage cycling 
trials, and the 3-stage cycling trials were then separated by 
48 h to ensure adequate recovery time. The exercise tests 
were performed at the same time each morning (between 
5:00-9:00 am), and trial order for the 3-stage cycling trials 
was randomised. Participants were instructed to refrain 
from alcohol, caffeine, and vigorous exercise in the 24 h 
prior to testing.     
 
Incremental cycling test to exhaustion 
All cycling tests were performed on an electronically-
braked cycle ergometer (Sport Excalibur, Lode B.V. Med-
ical Technology, Groningen, The Netherlands). Heart rate 
was monitored continuously throughout the incremental 
test (RS300X, Polar, Finland), and blood was sampled 
from the earlobe for the determination of blood [La-] (Lac-
tate Pro, ARKRAY Inc., Japan). Gas exchange variables 
were measured breath-by-breath using a calibrated meta-
bolic measurement system (CosMed, Pulmonary Function 
Equpiment, Quark CPET, Italy). Participants began the 
protocol by cycling at 15 W at a pedal cadence of 70-80 
rpm. Power output was increased by 15 W every 4 min un-
til blood [La-] reached a value of >4.0 mmol/L, after which 
the power output was increased by 15 W every 30 s until 
volitional exhaustion. When the required cadence could 
not be maintained despite strong verbal encouragement, 
the test was terminated. Peak HR and power output were 
recorded at this time. LT1 was calculated using the modi-
fied Dmax method (Cheng et al., 1992), and the final 30 s 
of oxygen consumption (VO2) data were averaged to deter-
mine peak VO2. 
 
3-stage cycling trials 
Participants ingested a core temperature (Tc) sensor (Cor-
Temp COR-100 Wireless Ingestible Temperature Sensor, 
HQ Inc., FL) ~8 h before each trial to allow adequate time 
for the pill to transit from the stomach to the small intes-
tines (Lee et al., 2000). Participants arrived to the labora-
tory in a fasted state and emptied their bladder before the 
measurement of body mass. Baseline Tc was recorded at 
this time. Participants then moved into the environmental 
chamber where they remained for 1 h to allow for passive 
acclimation. They were given a standardized breakfast in 
the chamber (1 piece of raisin toast per 50 kg of body mass 
and 0.3 piece for every 5 kg over 50 kg, and 5 mL water 
per kg of body mass), which they consumed within 30 min 





to allow for particle digestion prior to the commencement 
of exercise. After this time, no fluid or food was consumed 
until after the trial. After 1 h in the environment, resting Tc 
was recorded. During the two 3-stage cycling trials, partic-
ipants cycled at a cadence of 70-80 rpm at 90% (Stage 1), 
135% (Stage 2), and 180% (Stage 3) of LT1, as determined 
during the incremental cycle ergometer test. The length of 
each stage shortened as the trial progressed (Stage 1 = 30.0 
min, Stage 2 = 15.0 min, Stage 3 = 7.5 min; total = 52.5 
min) in order to prevent premature fatigue. Tc data were 
recorded at 7.5-min intervals throughout the trials. 
 
Blood and saliva sampling 
Blood samples (approximately 10 mL) were collected from 
the antecubital vein at baseline (room temperature), after 
60 min in the environmental condition, and immediately 
after exercise. Using whole blood, total white cell count, 
lymphocyte and monocyte counts, as well as hemoglobin 
and hematocrit were determined from vacutainer tubes 
containing EDTA (Becton–Dickinson, BD, Juiz de Fora, 
MG, Brazil) in a hematology analyzer (Ac.T™ 5 diff ana-
lyzer, Beckman Coulter, NZ). Venous blood samples were 
also collected into serum-separator tubes (Becton–Dickin-
son, BD, Juiz de Fora, MG, Brazil), stored in the dark for 
30 min and allowed to clot before being centrifuged for 10 
min at 3000 rev/min. Serum was separated into 500 uL al-
iquots and frozen at -80° C for the subsequent analyses of 
pro- and anti-inflammatory cytokines (IL-1β, IL-1RA, IL-
6, IL-8, IL-10 and TNF-α), CRP, and ovarian hormones.  
Cytokine analysis was completed using custom 
manufactured multiplex suspension array kits (Bio-Rad 
Laboratories Pty Ltd; Hercules, CA USA) according to the 
manufacturer’s instructions, and a Bioplex 200 Suspension 
Array Reader (Bio-Rad Laboratories Pty Ltd). Standard 
curves of cytokine concentration versus fluorescence in-
tensity were automatically generated by the Bioplex Man-
ager Software (Bio-Rad Laboratories Pty Ltd) and sample 
concentrations for each cytokine extrapolated from respec-
tive standard curves. All samples were analysed in dupli-
cate. 
CRP concentrations were determined via an immu-
noturbidimetric assay using commercially available rea-
gents and a COBAS Integra 400 system (Roche Diagnos-
tics, Mannheim, Germany). Ovarian hormone analysis was 
performed by a commercial pathology laboratory (ANZAC 
Institute, Sydney, Australia) using a stable-isotope dilution 
methodology in combination with liquid chromatography–
mass spectrometry. 
Baseline, pre-, and immediately post-exercise saliva 
samples were also collected. Unstimulated, whole saliva 
was collected using an IPRO oral fluid collector (OFC, 
IPRO Interactive, Wallingford, UK). Participants placed a 
OFC on the top of their tongue and closed their mouth. 
When 0.5 mL of saliva had been absorbed by the OFC, an 
indicator line on the OFC stem turned bright blue at which 
point the OFC was removed and placed into a 3 mL buffer 
solution. Mixing of the sample was performed by inverting 
the bottle with the OFC and buffer for 2 min to facilitate 
extraction of the target analyte. Bottles were stored at room 
temperature until two drops (using the dropper cap on the 
bottle) of the sample were used to determine salivary cor-
tisol concentration using an IPRO Lateral Flow Device 
(LFD) and Lateral Flow Reader (IPRO Interactive, Wall- 
ingford, UK).  The method and reliability of salivary corti-
sol analyses using the IPRO has been described in detail 
elsewhere (Fisher et al., 2016). 
 
Statistical analyses 
All statistical analyses were carried out using the IBM Sta-
tistical Package for the Social Sciences (SPSS Inc., Version 
24) software. Group characteristics were assessed using 
independent samples t-tests. As the data were normally dis-
tributed, fully factorial ANOVA with repeated measures 
(condition and time) were used to determine any main ef-
fects of, or interactions between, the three independent var-
iables i. Group (WomenNM and WomenOC), ii. Condition 
(TEMP and HEAT), and iii. Time (Baseline, Pre, Post) for 
the core temperature, cytokine, and cortisol data. Where 
statistically significant differences were detected, post hoc 
tests with Bonferroni adjustments were performed to detect 
where the differences occurred. All data are reported as 
means ± SD. p values are reported with significance set at 
< 0.05, and Cohen’s d (d) and partial eta-squared (ƞ2p) ef-
fect sizes are presented to indicate the magnitude of ob-
served effects for the outcome variables analysed using t-
tests and ANOVA, respectively. When interpreting effect 
sizes, .2, .5, and .8 and .01, .06, and .14 are considered 
small, medium, and large effect sizes for d and ƞ2p, respec-




Subject characteristics and incremental cycling test data 
are presented in Table 1. There were no between-group dif-
ferences in any of the subject characteristics or incremental 
cycling test values (p ≥ 0.16). However, 17β-estradiol 
(75.74 ± 57.21 pmol/L v 18.13 ± 20.18 pmol/L, p < 0.01, d 
= 1.34) and progesterone (0.24 ± 0.15 pmol/L v 0.12 ± 0.06 
pmol/L, p < 0.01, d = 1.05) were significantly higher in 
WomenNM compared to WomenOC, respectively. 
 
Table 1. Subject characteristics and peak values determined 
during incremental cycling to exhaustion in naturally-
menstruating women (WomenNM) and women using oral 
contraceptives (WomenOC). Values are mean (±standard 
deviation). 
 WomenNM (n = 8) 
WomenOC 
(n = 8) 
Age (yr) 22 (3) 22 (4) 
Body mass (kg) 63.1 (5.6) 59.5 (6.4) 
Height (m) 1.68 (.07) 1.64 (.06) 
Body mass index (kg/m2) 22.3 (1.8) 22.2 (1.9) 
Oxygen uptake  (L/min) 2.89 (.54) 2.66 (.45) 
Oxygen uptake (mL/kg/min) 44.8 (5.2) 44.5 (4.2) 
Power output (W) 241 (54) 227 (37) 
Blood lactate (mmol/L) 11.2 (1.3) 10.5 (.9) 
Heart rate (b/min) 193 (8) 195 (6) 
 
There were no differences in resting blood and im-
mune cell counts (Table 2) between WomenNM and Wom-
enOC (p ≥ 0.120). A trend (p = 0.07, d = 0.91) for higher 
CRP concentrations was noted for WomenOC (1.102 ± 




1.182 mg/L), with a value more than three-fold higher than 
that observed in WomenNM (0.326 ± 0.228 mg/L).  
Table 3 presents the environmental data, as well as 
the exercise intensities utilised during the 3-stage cycling 
trials. There were no differences between WomenNM and 
WomenOC for ambient temperature (p ≥ 0.410), humidity 




Table 2. Resting blood and immune cell counts in naturally-menstruating women (WomenNM) and 





White blood cells (5.34×10^9/L) 5.47 (.85) 6.47 (1.60) 
Red blood cells (5.34×10^12/L) 5.34 (1.07) 5.17 (.70) 
Hemoglobin (g/L) 158.15 (29.42) 151.39 (26.34) 
Hematocrit (L/L) .46 (.09) .45 (.08) 
Platelets (5.34×10^9/L) 215.17 (71.42) 255.15 (62.51) 
Neutrophils (5.34×10^9/L) 2.52 (.47) 3.17 (1.20) 
Lymphocytes (5.34×10^9/L) 2.22 (.47) 2.56 (.72) 
Monocytes (5.34×10^9/L) .43 (.12) .50 (.17) 
Eosinophils (5.34×10^9/L) .22 (.14) .23 (.14) 
Basophils (5.34×10^9/L) .11 (.10) .18 (.22) 
 
Table 3. 3-stage cycling test conditions. Values are mean (±standard deviation). 
 WomenNM (n = 8)
WomenOC 
(n = 8) 
Ambient temperature (°C)       TEMP trial   22 (1) 22 (1) 
                                                     HEAT trial  35 (1) 35 (1) 
Humidity (%)                            TEMP trial   65 (5) 60 (10) 
                                                    HEAT trial  39 (4) 35 (10) 
Power output (W)                         Stage 1 73 (24) 64 (16) 
                                                        Stage 2 109 (36) 96 (24) 
                                                        Stage 3 145 48) 128 (31) 
TEMP = 3-stage cycling test performed in temperate conditions; HEAT = 3-stage cycling test performed in hot condi-
tions. There were no significant differences between WomenNM and WomenOC in any of the variables (p > 0.05). 
 
Table 4. Core temperature, cortisol, and cytokine concentrations before and after the 3-stage cycling tests in naturally-
menstruating women (WomenNM) and women using oral contraception (WomenOC). Values are mean (±standard deviation). 
  WomenNM WomenOC 
  TEMP HEAT TEMP HEAT 
Tc (°C) Baseline 37.1 (.2) 37.0 (.4) 37.5 (.2) † 37.6 (.3) †  
 Pre 37.0 (.2) 37.0 (.3) 37.4 (.1) † 37.5 (.3) †  
 Post 38.1 (.3) #§ 38.4 (.4) #§* 38.2 (.2) #§ 38.5 (.3) #§* 
Cortisol  Baseline 13.62 (7.82) 17.26 (9.08) 16.66 (5.85) 20.59 (8.71) 
(nmol/L) Pre 7.88 (4.19) 14.09 (11.35) 14.18 (3.47) 17.88 (3.66) 
 Post 6.57 (4.09) #§ 12.76 (10.24) * 11.89 (5.05) 15.11 (5.70) 
IL-1β 
(pg/mL) 
Pre .38 (.33) .43 (.36) .29 (.12) .36 (.15) 
Post .42 (.33) .42 (.39) .32 (.12) .34 (.10) 
Post .39 (.27) .37 (.38) .28 (.09) .31 (.13) 
IL-1ra 
(pg/mL) 
Baseline 50.22 (38.81) 48.90 (38.43) 27.12 (13.79) 35.05 (14.75) 
Pre 45.22 (37.57) 49.36 (35.94) 32.28 (12.32) 44.43 (28.34) 
Post 50.46 (39.03) 54.86 (35.35) 32.11 (9.81) 41.90 (29.69) 
IL-6   
(pg/mL) 
Baseline 5.24 (9.71) 3.33 (7.41) .95 (.80) 1.44 (1.24) 
Pre 4.92 (9.02) 3.07 (6.45) .77 (.87) 1.45 (1.18) 
Post 5.82 (10.17) 3.88 (8.12) .84 (.83) 1.07 (.83) 
IL-8  
(pg/mL) 
Baseline 4.66 (.89) 9.56 (3.76) * 3.91 (1.40) 10.68 (10.33) * 
Pre 4.17 (.73) 8.78 (4.60) * 3.67 (1.41) 7.43 (4.10) * 
Post 5.02 (1.02) 5.88 (1.94) # 4.28 (2.30) 5.69 (4.14) # 
IL-10 
(pg/mL) 
Baseline 4.58 (2.60) 4.20 (.62) 4.20 (1.78) 4.91 (2.33) 
Pre 4.76 (2.47) 4.36 (1.38) 4.61 (2.26) 5.30 (2.40) 
Post 4.98 (2.92) 3.99 (.55) 4.38 (1.96) 4.59 (2.01) 
TNF-α 
(pg/mL) 
Baseline 9.28 (11.48) 6.88 (10.28) 4.68 (41.79) 4.31 (1.49) 
Pre 9.41 (11.92) 7.55 (8.21) 4.63 (3.03) 4.93 (1.42) 
Post 9.42 (10.82) 7.02 (8.48) 3.25 (1.38) 4.12 (.65) 
TEMP = 3-stage cycling test performed in temperate conditions; HEAT = 3-stage cycling test performed in hot conditions; Pre = after 1 hr resting 
in the testing conditions; Post = immediately after completion of the 3-stage cycling test; Tc = core temperature. † Significantly different from 
WomenNM at the same time point (p ≤ 0.004). * Significantly different from the TEMP trial at the same time point (p ≤ 0.004). # Significantly 










 All Tc, cortisol, and cytokine data are presented in Ta-
ble 4. In both the TEMP and HEAT trials, respectively, Tc 
was higher in WomenOC than WomenNM at baseline (p ≤ 
0.002, ƞ2p = 0.530, 0.491) and pre-exercise (p ≤ 0.004, ƞ2p 
= 0.521, 0.452) but not post-exercise (p ≥ 0.259, ƞ2p = 
0.090, 0.022), and the Tc reached at the cessation of exer-
cise was higher in the HEAT trial compared to the TEMP 
trial irrespective of group (p = 0.006, ƞ2p = 0.433).  
Main effects for condition (p = 0.019, ƞ2p = 0.335) 
and time (p = 0.004, ƞ2p = 0.321) were  observed for sali-
vary cortisol, in that cortisol was significantly higher in the 
HEAT trial, and decreased over time in both experimental 
conditions. No significant differences were observed be-
tween WomenNM and WomenOC (p = 0.097), although 
WomenOC typically had higher cortisol concentrations as 
indicated by a large effect size (ƞ2p = 0.184).  
There was no effect of group (p > 0.05), condition 
(p > 0.05), or time (p > 0.05) for IL-1β, IL-1ra, IL-6, IL-
10, and TNF-α. IL-8 was not different between WomenNM 
and WomenOC (p = 0.742, ƞ2p = 0.007), however a condi-
tion × time interaction was observed (p = 0.004, ƞ2p = 
0.296) whereby IL-8 was significantly elevated in both 
groups in the HOT trial at baseline (p = 0.004, ƞ2p = 0.415) 
and after resting in the heat for 1 h (p = 0.001, ƞ2p = 0.512), 
but not after completion of the 3-stage cycling test (p = 




In the present study, no differences were found between 
long-term oral contraceptive users (during the active pill 
phase) and normally menstruating women (during the early 
follicular phase) in resting blood and immune cell counts, 
or the cortisol and cytokine response to performing exer-
cise in temperate and hot ambient environments. There was 
a trend for elevated resting CRP in WomenOC (p = 0.07), 
which could be indicative of inflammation. For the most 
part, however, the results obtained in the current study in-
dicate similar immunoendocrine function in WomenOC 
and WomenNM at rest and after exercise in both the TEMP 
and HEAT conditions. 
To the authors’ knowledge, no previous research 
has examined the combined effect of heat and exercise on 
the immune and stress response of OC users when com-
pared to normally-menstruating women. Previously, the 
select studies that have investigated immune function in 
OC users under temperate conditions have found varying 
results, with some indicating a protective anti-inflamma-
tory environment (e.g., Giraldo et al., 2008) and others sug-
gesting increased inflammation (e.g., Timmons et al., 
2005). The present findings showed a comparable response 
between WomenNM and WomenOC for all of the pro- (IL-
1β, IL-6, IL-8, TNF-α) and anti-inflammatory (IL-1ra, IL-
6, IL-10) cytokines measured, both at rest and after exer-
cise in the TEMP and HEAT environments. Surprisingly, 
there was no increase in cytokine concentrations in re-
sponse to the exercise protocol (in either environmental 
condition), which contradicts a considerable body of re-
search that reports increased cytokine concentrations post-
exercise (see reviews: Pedersen, 2000; Pedersen et al., 
1998). It is unclear why the exercise protocol utilised in the 
present study did not induce immune changes, although 
previous research has shown considerable differences in 
the exercise-induced immune response depending on the 
exercise duration (Ostrowski et al., 1998), mode (Nieman 
et al., 1998), core temperature reached (Rhind et al., 2004), 
and the participants’ training status (Evans et al., 1986). In-
deed, a reduced IL-6 response has been observed when 
comparing cycling exercise (as was used in the present 
study) to running (Nieman et al., 1998). In support of this, 
Ullum et al. (1994) found no changes in plasma IL-1α, IL-
1β, and TNF-α in response to 1 h of bicycle exercise at 75% 
VO2max. Starkie et al. (2005) also reported no change in 
plasma concentrations of IL-6 or TNF-α after cycling in 
cool conditions for 90 min at 70% peak VO2, although cy-
cling in a hot environment did elicit a cytokine response. 
The reason this was not replicated during the HEAT trial 
in the present study is not immediately clear, although it 
should be noted that Starkie and colleagues (Starkie et al., 
2005) utilised a different protocol (i.e., fixed intensity), 
participant group (i.e., males), and participant training sta-
tus (i.e., endurance-trained) to that employed in the current 
research, which may help to explain the inconsistent find-
ings.  
Rhind and colleagues (2004) highlighted the im-
portance of elevated core temperature in instigating an im-
mune response, reporting no increase in cytokine concen-
trations during or after cycling exercise when core body 
temperature was clamped at near-resting levels (via cold 
water immersion). Conversely, significant increases in IL-
1ra, IL-6, IL-12, and TNF-α concentrations were observed 
in the same study when core temperature rose to 39.1 ± 
0.20°C during exercise in hot water (39°C). Interestingly, 
while significantly higher at the cessation of exercise, IL-
1ra and IL-6 were not elevated after 20 min of hot-water 
exercise despite a core temperature increase from 37.2 ± 
0.20°C to 38.2 ± 0.36°C. This suggests that a core temper-
ature threshold has to be reached before certain cytokine 
concentrations will detectably increase. Thus, it is possible 
that the moderate hyperthermia achieved by participants in 
the current research (Tc ≤ 38.5°C in all trials), in concert 
with the low-impact cycling protocol, may not have been 
sufficient to induce a detectable cytokine response. It 
should also be noted that IL-8 was significantly elevated in 
both WomenNM and WomenOC in the HEAT trial at base-
line and after resting in the heat, but not after completion 
of the 3-stage cycling test. It is unclear as to why this oc-
curred, however this result is not likely to be practically 
meaningful as the concentrations reported upon comple-
tion of the cycling protocol were comparable to that ob-
served in the TEMP trial. 
There was no statistically significant difference in 
salivary cortisol between OC users and non-users (p = 
0.97), although a large effect size (ƞ2p = .184) indicated that 
cortisol concentrations were generally higher in Wom-
enOC when compared to WomenNM. Previous studies 
have been highly variable when comparing resting cortisol 
values between eumenorrheic women and women on OC, 
with some showing an elevation (Boisseau et al., 2013; 
Timmons et al., 2005), others showing no difference 




(Bonen et al., 1991; Kirschbaum et al., 1996), and one 
showing a decreased concentration (Reinberg et al., 1996) 
in OC users. However, of the three existing studies that 
have investigated the cortisol response of OC users to ex-
ercise (albeit in temperate conditions) (Boisseau et al., 
2013; Bonen et al., 1991; Kirschbaum et al., 1996), all have 
observed a blunted cortisol response to exercise when com-
pared to normally-menstruating women, which was not 
found in the present study. Rather, both groups reported 
similarly decreased salivary cortisol concentrations after 
the exercise protocol when compared to baseline and rest-
ing values. This is in opposition to most previous research 
(e.g., Niess et al., 2003; Rhind et al., 2004; Starkie et al., 
2005), which reports exercise-induced increases in cortisol 
concentrations. While the current findings oppose the ma-
jority of previous literature, they are not entirely unprece-
dented; Hoffman et al. (1997) reported decreased cortisol 
concentrations immediately post a high-intensity cycling 
protocol in both temperate (22°C) and hot (35°C) condi-
tions, and Francesconi et al. (1985) found that plasma cor-
tisol decreased over the course of a light exercise protocol 
performed in a very hot environment (49°C). The authors 
of these studies suggest that the circadian variation in cor-
tisol could have been at least partially responsible for the 
observed decrement, as there is evidence to suggest that it 
moderates the cortisol response to exercise (Thuma et al., 
1995). Thus, it is possible that the morning testing sessions 
utilised in the present research coincided with a natural de-
cline from participants’ circadian peak. However, it should 
be noted that some earlier studies have reported increases 
in cortisol concentrations in response to morning exercise 
(Rhind et al., 2004; Starkie et al., 2005), and so the reasons 
behind this disparity remain unclear. Nevertheless, no dif-
ferences in salivary cortisol concentrations were observed 
according to OC use, which was the focus of the present 
study. The paucity of research investigating the cortisol re-
sponse to exercise in OC users, especially in hot ambient 
conditions, necessitates that considerably more research is 
conducted before the effects of OC use on the stress re-
sponse can be fully understood.   
Comparable immune cell counts were observed in 
OC users and non-users in the present study, which gener-
ally supports previous research that has found no apparent 
differences between OC users and non-users in resting neu-
trophil, monocyte, and lymphocyte counts (Timmons et al., 
2005). However, this earlier study did observe higher leu-
kocyte counts in OC users at rest (Timmons et al., 2005), 
whereas no differences in white blood cell counts were 
found between the current cohorts. The present study did 
observe a trend (p = 0.07) for elevated resting CRP con-
centrations in WomenOC, which supports a number of pre-
vious studies that have reported elevated CRP in women 
on OC when compared to their normally menstruating 
counterparts (Cauci et al., 2008; Cauci et al., 2017; 
Sørensen et al., 2014; van Rooijen et al., 2006). Interest-
ingly, a recent study found that CRP concentrations are sig-
nificantly higher in the follicular phase of the menstrual cy-
cle when compared to the luteal phase (Vashishta et al., 
2017), and WomenNM in the present study were tested in 
the follicular phase of their cycle in order to isolate the ef-
fects of the exogenous hormones contained in the OC pill. 
This cyclical variation in CRP likely reduced the magni-
tude of difference between WomenNM and WomenOC for 
this particular measure, and may help to explain why the 
CRP results fell short of reaching statistical significance. 
Importantly, however, a CRP value of > 1 as observed in 
WomenOC indicates a moderate cardiovascular disease 
risk (whereas WomenNM fell into the low-risk category) 
(Ridker, 2003). Thus, the current results may be clinically 
relevant despite not being statistically different.  
While the current study reflects a significant ad-
vancement in the scientific knowledge regarding OC use 
and immunoendocrine function, there are some limitations 
that should be addressed in future studies. Firstly, the tim-
ing of blood sampling (i.e., immediately post exercise) may 
not have captured the exercise- and heat-induced immune 
response in its entirety, with some cytokines (e.g., IL-1ra) 
showing peak concentrations > 1 h after exercise  
(Ostrowski et al., 1998; Ostrowski et al., 1999). However, 
peak IL-6, IL-10, and TNF-α cytokine concentrations have 
been shown to occur immediately after exercise (Ostrowski 
et al., 1998; Ostrowski et al., 1999), and thus, increases in 
these cytokine concentrations should have been detected 
by the sampling protocol had they occurred. Future studies 
should also endeavour to use larger participant numbers to 
ensure all meaningful differences are captured during anal-
ysis. It is possible that the large difference in mean CRP 
observed in the present study was not statistically signifi-
cant due to the relatively small number of subjects utilised 
(n = 9 in each group). Lastly, given the cyclical variation 
that occurs across the menstrual cycle (i.e., in CRP) in eu-
menorrheic women, future research should include addi-
tional testing sessions at different points throughout the cy-
cle, as well as during the inactive pill phase, in order to 




No previous studies have examined the combined effect of 
heat and exercise on the immunoendocrine response of OC 
users when compared to eumenorrheic women. WomenOC 
and WomenNM exhibited comparable immune (i.e., cyto-
kines) and stress (i.e., cortisol) responses both at rest and 
during exercise in temperate and hot conditions. Moreover, 
there were no differences in resting blood and immune cell 
counts between WomenOC and WomenNM. However, 
resting CRP was more than three times higher in Wom-
enOC compared to WomenNM, and their value of > 1 in-
dicates a moderate risk of developing cardiovascular dis-
ease. Future studies are required to provide a more com-
prehensive understanding of the effects of OC use (or lack 
thereof) on immunoendocrine function, particularly during 
exercise in the heat.   
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 No previous study has investigated the combined ef-
fect of heat and exercise on the immune response of 
women taking oral contraceptives 
 Resting C-reactive protein was more than three times 
higher in the women taking the active oral contracep-
tive pills compared to naturally menstruating women 
during the early follicular phase 
 There were no differences in resting immune cell 
counts between groups, nor any differences in cortisol 
or any of the pro- or anti-inflammatory cytokines 
measured at rest or after completion of the exercise 
trials 
 With the exception of C-reactive protein, women us-
ing oral contraceptives exhibit similar immunoendo-
crine function to naturally menstruating women both 
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